IL292889A - Methods for the treatment of warm autoimmune hemolytic anemia using anti-fcrn antibodies - Google Patents
Methods for the treatment of warm autoimmune hemolytic anemia using anti-fcrn antibodiesInfo
- Publication number
- IL292889A IL292889A IL292889A IL29288922A IL292889A IL 292889 A IL292889 A IL 292889A IL 292889 A IL292889 A IL 292889A IL 29288922 A IL29288922 A IL 29288922A IL 292889 A IL292889 A IL 292889A
- Authority
- IL
- Israel
- Prior art keywords
- riu0003
- wkhu0003
- ruu0003
- khu0003
- dqu0003
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962937395P | 2019-11-19 | 2019-11-19 | |
| PCT/US2020/061028 WO2021101975A1 (en) | 2019-11-19 | 2020-11-18 | Methods of treating warm autoimmune hemolytic anemia using anti-fcrn antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL292889A true IL292889A (en) | 2022-07-01 |
Family
ID=73854886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL292889A IL292889A (en) | 2019-11-19 | 2020-11-18 | Methods for the treatment of warm autoimmune hemolytic anemia using anti-fcrn antibodies |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230049011A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4061486A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7722991B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114728180A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020387399A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3157797A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL292889A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022005862A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202132346A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021101975A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117693523A (zh) * | 2021-08-13 | 2024-03-12 | 舒泰神(北京)生物制药股份有限公司 | 特异性识别fcrn的抗体及其用途 |
| AU2023281650A1 (en) | 2022-05-30 | 2024-10-17 | Hanall Biopharma Co., Ltd. | Anti-fcrn antibody or antigen binding fragment thereof with improved stability |
| JP2025528527A (ja) * | 2022-09-06 | 2025-08-28 | イミュノバント・サイエンシズ・ゲーエムベーハー | 抗FcRN抗体を用いたグレーブス病の治療方法 |
| WO2026136830A1 (en) * | 2024-12-20 | 2026-06-25 | Paragon Therapeutics, Inc. | Anti-fcrn antibodies and methods of use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4241852A3 (en) | 2014-04-30 | 2023-11-15 | Hanall Biopharma Co., Ltd. | Antibody binding to fcrn for treating autoimmune diseases |
| US10336825B2 (en) * | 2014-04-30 | 2019-07-02 | Hanall Biopharma Co., Ltd. | Antibody binding to FcRn for treating autoimmune diseases |
| JP6853178B2 (ja) * | 2015-01-30 | 2021-03-31 | モメンタ ファーマシューティカルズ インコーポレイテッド | FcRn抗体およびその使用方法 |
| CA3022547A1 (en) * | 2015-05-12 | 2016-11-17 | Syntimmune, Inc. | Humanized affinity matured anti-fcrn antibodies |
| BR112019001806A2 (pt) * | 2016-07-29 | 2019-05-07 | Momenta Pharmaceuticals, Inc. | anticorpos para fcrn e métodos de uso dos mesmos |
| EP3762027A4 (en) * | 2018-02-13 | 2022-06-15 | The Brigham & Women's Hospital, Inc. | THERAPEUTIC FCRN-BASED BISPECIFIC MONOCLONAL ANTIBODIES |
-
2020
- 2020-11-18 EP EP20825291.6A patent/EP4061486A1/en active Pending
- 2020-11-18 CA CA3157797A patent/CA3157797A1/en active Pending
- 2020-11-18 MX MX2022005862A patent/MX2022005862A/es unknown
- 2020-11-18 IL IL292889A patent/IL292889A/en unknown
- 2020-11-18 CN CN202080080573.3A patent/CN114728180A/zh active Pending
- 2020-11-18 US US17/777,913 patent/US20230049011A1/en active Pending
- 2020-11-18 AU AU2020387399A patent/AU2020387399A1/en not_active Abandoned
- 2020-11-18 JP JP2022529066A patent/JP7722991B2/ja active Active
- 2020-11-18 WO PCT/US2020/061028 patent/WO2021101975A1/en not_active Ceased
- 2020-11-18 TW TW109140405A patent/TW202132346A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3157797A1 (en) | 2021-05-27 |
| MX2022005862A (es) | 2022-06-23 |
| AU2020387399A1 (en) | 2022-05-19 |
| CN114728180A (zh) | 2022-07-08 |
| US20230049011A1 (en) | 2023-02-16 |
| TW202132346A (zh) | 2021-09-01 |
| WO2021101975A1 (en) | 2021-05-27 |
| EP4061486A1 (en) | 2022-09-28 |
| JP7722991B2 (ja) | 2025-08-13 |
| JP2023502398A (ja) | 2023-01-24 |
| KR20220100880A (ko) | 2022-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yoshihara et al. | Chemical interaction of glycero-phosphate dimethacrylate (GPDM) with hydroxyapatite and dentin | |
| Yoshihara et al. | Nano-controlled molecular interaction at adhesive interfaces for hard tissue reconstruction | |
| DE102008042212A1 (de) | Reflektives optisches Element und Verfahren zu seiner Herstellung | |
| EP1318844B1 (de) | Oberflächenmodifizierte implantate | |
| Bosco et al. | Hydroxyapatite nanocrystals functionalized with alendronate as bioactive components for bone implant coatings to decrease osteoclastic activity | |
| IL275004B2 (en) | Battery swapping station and control method therefor | |
| KR102497107B1 (ko) | 플로라이드(Flouride)로 도핑되고 구연산염으로 코팅된 비정질 인산칼슘 나노입자를 얻기 위한 공정 | |
| AU2003210787A1 (en) | Phosphorus-containing compounds & uses thereof | |
| EA011488B1 (ru) | Фосфорсодержащие соединения и их получение | |
| EP3253740A1 (en) | Amorphous trisodium sacubitril valsartan and a process for the preparation thereof | |
| KR20110059546A (ko) | 스트론튬 염,비타민 d 및 시클로덱스트린을 포함하는 약제 조성물 | |
| JP3853785B2 (ja) | 口腔用組成物 | |
| EP3663264A1 (en) | Method for producing zirconia particle-containing powder | |
| Cunha-Filho et al. | Characterization of β-lapachone and methylated β-cyclodextrin solid-state systems | |
| EP1603525B1 (en) | Oral preparation system | |
| WO2022089885A1 (de) | Optisches element, insbesondere zur reflexion von euv-strahlung, optische anordnung und verfahren zum herstellen eines optischen elements | |
| CA2480125C (en) | Use of carbon-2-modified-19-nor-vitamin d analogs to induce the formation of new bone | |
| DE102022203644A1 (de) | Verfahren zum Herstellen eines Substrats und eines reflektiven optischen Elements für die EUV-Lithographie | |
| EP2773629B1 (en) | Process for the preparation of an amorphous form of cabazitaxel | |
| IL292204B2 (en) | A conveyor device for at least transferring a liquid and a pump comprising such a conveyor device | |
| WO1999031112A1 (de) | Vitamin d-derivate mit phosphoratomen in den seitenketten | |
| Sternitzke et al. | Strontium hydroxyapatite and strontium carbonate as templates for the precipitation of calcium-phosphates in the absence and presence of fluoride | |
| WO2010043215A1 (de) | Verfahren zur herstellung photokatalytisch aktiver titandioxidschichten | |
| IL276083B2 (en) | Security door mounting arrangement | |
| US20010051738A1 (en) | Crystalline1alpha,24(S)-dihydroxyvitamin D2 and method of purification thereof |